Prognostic value of three molecular forms of prostate-specific antigen ratios in patients with prostate adenocarcinoma.

[1]  E. Higashihara,et al.  Comparisons of the Various Combinations of Free, Complexed, and Total Prostate–Specific Antigen for the Detection of Prostate Cancer , 2000, European Urology.

[2]  D. Chan,et al.  Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. , 2000, The Journal of urology.

[3]  E. Higashihara,et al.  Comparison of two investigative assays for the complexed prostate-specific antigen in total prostate-specific antigen between 4.1 and 10.0 ng/mL. , 2000, Urology.

[4]  J. Richie,et al.  Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial. , 1999, The Journal of urology.

[5]  Higashihara,et al.  Preoperative nested reverse transcription‐polymerase chain reaction for prostate specific membrane antigen predicts biochemical recurrence after radical prostatectomy , 1999, BJU international.

[6]  Morote,et al.  The free‐to‐total serum prostatic specific antigen ratio as a predictor of the pathological features of prostate cancer , 1999, BJU international.

[7]  F. España,et al.  Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples. , 1998, Journal of Urology.

[8]  P. Schellhammer,et al.  Percent free prostate-specific antigen values in men with recurrent prostate cancer after radical prostatectomy. , 1998, Urology.

[9]  A W Partin,et al.  Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. , 1998, JAMA.

[10]  J. Pannek,et al.  The use of percent free prostate specific antigen for staging clinically localized prostate cancer. , 1998, The Journal of urology.

[11]  G van den Engh,et al.  Cell-cell interaction in prostate gene regulation and cytodifferentiation. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[12]  B. G. Blijenberg,et al.  The free-to-total serum prostate specific antigen ratio for staging prostate carcinoma. , 1997, The Journal of urology.

[13]  J. Kawamura,et al.  Change in morphological and functional cytodifferentiation induced by seminal vesicle mesenchyme in cell suspensions of rat Dunning prostatic adenocarcinoma cells , 1996, International journal of cancer.

[14]  J. Pannek,et al.  The role of free/total prostate-specific antigen ratio in the prediction of final pathologic stage for men with clinically localized prostate cancer. , 1996, Urology.

[15]  A W Partin,et al.  Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. , 1996, Urology.

[16]  L. Baert,et al.  Free-to-total prostate specific antigen ratio as a single test for detection of significant stage T1c prostate cancer. , 1996, The Journal of urology.

[17]  J. Oesterling,et al.  Free, complexed, and total serum prostate-specific antigen concentrations and their proportions in predicting stage, grade, and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate. , 1996, Urology.

[18]  P. Carroll,et al.  Comparison of prostate specific antigen with prostate specific antigen density for 3 clinical applications. , 1994, The Journal of urology.

[19]  D. Bostwick,et al.  Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer. , 1994, The Journal of urology.

[20]  D. Chan,et al.  The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. , 1993, The Journal of urology.

[21]  H. Lilja,et al.  Prostate specific antigen predominantly forms a complex with alpha1‐antichymotrypsin in blood. Implications for procedures to measure prostate specific antigen in serum , 1992, Cancer.

[22]  O. Nilsson,et al.  Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. , 1991, Clinical chemistry.

[23]  J. Oesterling,et al.  Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. , 1991, The Journal of urology.

[24]  S. Loening,et al.  Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer? , 2000, Clinical chemistry.

[25]  T. Stamey,et al.  Examination of the 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy: relationship to transition zone volume. , 2000, The Journal of urology.

[26]  U. Stenman,et al.  A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. , 1991, Cancer research.